2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Corporate
| General Corporate — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Hogan Lovells |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| General Corporate — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Dechert |
| Fenwick & West |
| Gibson Dunn & Crutcher |
| Jones Day |
| Morgan Lewis & Bockius |
| Sidley Austin |
| Wilson Sonsini Goodrich & Rosati |
General Patent Litigation
| General Patent Litigation — Recommended |
|---|
| Arnold & Porter |
| Cooley |
| Covington & Burling |
| Durie Tangri |
| Gibson Dunn & Crutcher |
| Knobbe Martens |
| Mayer Brown |
| McAndrews Held & Malloy |
| Morgan Lewis & Bockius |
| Sterne Kessler Goldstein & Fox |
| Venable |
| Weil Gotshal & Manges |
Hatch-Waxman Patent Litigation (Branded)
| Hatch-Waxman Patent Litigation (Branded) — Highly Recommended |
|---|
| Covington & Burling |
| Finnegan Henderson Farabow Garrett & Dunner |
| Fish & Richardson |
| Paul Hastings |
| Sidley Austin |
| Venable |
| Williams & Connolly |
| WilmerHale |
| Hatch-Waxman Patent Litigation (Branded) — Recommended |
|---|
| Arnold & Porter |
| Bartlit Beck |
| Dechert |
| Jones Day |
| Kirkland & Ellis |
| Latham & Watkins |
| Mayer Brown |
| O'Melveny & Myers |
| Quinn Emanuel Urquhart & Sullivan |
Licensing & Collaboration
| Licensing & Collaboration — Highly Recommended |
|---|
| Cooley |
| Covington & Burling |
| Goodwin Procter |
| Latham & Watkins |
| Ropes & Gray |
| WilmerHale |
| Wilson Sonsini Goodrich & Rosati |
| Licensing & Collaboration — Recommended |
|---|
| Baker McKenzie |
| Dechert |
| Fenwick & West |
| Hogan Lovells |
| Jones Day |
| King & Spalding |
| Morgan Lewis & Bockius |
| Sidley Austin |
Mergers & Acquisitions
| Mergers & Acquisitions — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Kirkland & Ellis |
| Latham & Watkins |
| Ropes & Gray |
| Skadden Arps Slate Meagher & Flom |
| Mergers & Acquisitions — Recommended |
|---|
| Arnold & Porter |
| Covington & Burling |
| Gibson Dunn & Crutcher |
| Hogan Lovells |
| Sidley Austin |
| WilmerHale |
Patent Prosecution
Patent Strategy & Management
| Patent Strategy & Management — Recommended |
|---|
| Arnold & Porter |
| Dechert |
| Fenwick & West |
| Foley & Lardner |
| Greenberg Traurig |
| Hamilton Brook Smith & Reynolds |
| Leydig Voit & Mayer |
| McDonnell Boehnen Hulbert & Berghoff |
| Morgan Lewis & Bockius |
| Venable |
| WilmerHale |
Venture Capital
| Venture Capital — Highly Recommended |
|---|
| Cooley |
| Goodwin Procter |
| Latham & Watkins |
| Wilson Sonsini Goodrich & Rosati |
| Venture Capital — Recommended |
|---|
| Gunderson Dettmer |
| Hogan Lovells |
| Mintz Levin Cohn Ferris Glovsky and Popeo |
| Ropes & Gray |
| WilmerHale |
White-Collar/Govt. Investigations
| White-Collar/Government Investigation — Highly Recommended |
|---|
| Cleary Gottlieb Steen & Hamilton |
| Cooley |
| Covington & Burling |
| Gibson Dunn & Crutcher |
| Hogan Lovells |
| King & Spalding |
| Morgan Lewis & Bockius |
| Ropes & Gray |
| Sidley Austin |
| WilmerHale |
| White-Collar/Government Investigation — Recommended |
|---|
| Arnold & Porter |
| Goodwin Procter |
| Latham & Watkins |
| McDermott Will & Emery |
| Schulte Roth & Zabel |
| White & Case |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Barrett, Steven D | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | Boston |
| Bassett, David B | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | New York City |
| Bongiorno, Michael | Non-IP Litigation & Enforcement | Product Liability | New York City |
| Der Marderosian, Lia | Financial & Corporate | Corporate | Boston |
| Falber, Stuart | Financial & Corporate | Corporate | Boston |
| Gunther, Robert J | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | New York City |
| Gurney, Brent | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Washington, D.C. |
| Hogan, Sarah | Financial & Corporate | Licensing & Collaboration | Boston |
| Jonas, Stephen | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Boston |
| Juran, Belinda | Boston | ||
| Lee, William F | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Boston |
| Manheim, Bruce | Regulatory | FDA: Pharmaceutical | Washington, D.C. |
| Mazareas, Cynthia | Financial & Corporate | Corporate | Boston |
| Pirozzolo, Lisa J | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Boston |
| Schulman, Emily | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Boston |
| Selwyn, Mark D | Intellectual Property | General Patent Litigation | Palo Alto |
| Shapiro, Howard | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Washington, D.C. |
| Singer, Steven D | Financial & Corporate | Corporate, Venture Capital, Licensing & Collaboration, Mergers & Acquisitions | New York City |
| Superko, Colleen | Intellectual Property | Patent Prosecution, Patent Strategy & Management, Hatch-Waxman Patent Litigation | Boston |
| Whelan, Emily R | Intellectual Property | Patent Prosecution, Patent Strategy & Management, General Patent Litigation, Hatch-Waxman Patent Litigation | Boston |
| Wigmore, Amy | Intellectual Property | General Patent Litigation, Hatch-Waxman Patent Litigation | Washington, D.C. |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Financial & Corporate
WilmerHale
Dual-headquartered in Boston and Washington DC, WilmerHale offers life sciences companies a full range of corporate and finance-related legal services. One peer notes the firm has "excellent lawyers" in the space while another peer highlights their "great reputation" in Boston.
Steven Barrett is co-chair of the firm's technology transactions and licensing practice group. Recently, Barrett represented Ribometrix in a collaboration with Vertex Pharmaceuticals, and Medtronic in funding agreements with Blackstone Life Sciences.
Life sciences group co-chair Stuart Falber advises a variety of life sciences clients ranging from startups to established companies in the space. He specializes in corporate and venture capital transactions, as well as licensing and collaboration agreements. Among his notable matters, Fabler advised Epizyme in its $270 million collaboration agreement with Royalty Pharma.
Operating from both the firm's Boston and New York offices, Steven Singer has over 30 years of experience assisting both public and private life sciences companies in various transactions. Among his recent clients, Singer represented Fulcrum Therapeutics in its $72 million IPO.
Lia Der Marderosian is chair of the firm's transactional department and advises life sciences clients in a variety of corporate matters, including offerings, transactions, and governance. Among her recent matters, Der Marderosian represented Pandion Theraupetics, a biotechnology company focused on autoimmune diseases, in its $80 million Series B financing.
A new addition to this year’s list is Cynthia Mazareas, who represents both a number of high-profile private and public life sciences companies with a variety of issued related to corporate governance and transactions. In the last year, Mazareas served as lead lawyer for Schrödinger in its $232 million IPO as well as Imara’s IPO, valued at $86.5 million.
Intellectual Property
WilmerHale
WilmerHale's life sciences IP group is highly recommended for general patent litigation and Hatch-Waxman disputes for branded drug makers. The firm is also notable for its expertise in patent prosecution and post-grant proceedings. "I have worked with and against this firm and find their work to be top-notch," a peer says about the litigation practice.
William Lee is one of the most celebrated patent litigators in the country, offering more than four decades of experience in law. Although his practice spans industries outside of life sciences, he is often involved in key patent disputes facing the firm’s life sciences clients. IP litigation group co-chair Lisa Pirozzolo is an experienced first-chair trial lawyer who is representing several notable life sciences clients, including CSL Behring in a dispute against Biogen related to hemophilia treatment.
New York partner Robert Gunther is a key member of the firm’s life sciences patent litigation bench, and was honored in 2020 as the General Patent Litigator of the Year in New York for his significant activity in the area. Among his notable representations was a consolidated case for Roche and Becton Dickinson against Enzo Life Sciences, which resulted in a noteworthy Federal Circuit ruling involving enablement issues. The matter was named one of 2020’s Patent Impact Cases of the Year and Gunther in part won the Litigator of the Year award due to his involvement.
DC-based partner Amy Wigmore is currently active for Bristol-Myers Squibb and Pfizer in a Hatch-Waxman litigation opposite several generic manufacturers that at one point totaled 25 challengers. PTAB expert Emily Whelan was active alongside Wigmore in the matter, and is separately involved in a Hatch-Waxman dispute for Akebia and Keryx involving 14 patents related to its Auryxia drug.
Patent attorney Colleen Superko specializes in portfolio development, strategic counseling and licensing, among other areas. She currently assists H Lundbeck with several patent portfolios and related PTAB challenges.
Life Cycle
WilmerHale
WilmerHale is recognized as a leading firm in the life sciences sector for its multifaceted practice assisting companies in pre- to post-market matters. The firm is graded highly in a number of legal disciplines, including patent litigation, white-collar matters, licensing and collaboration, and general corporate work.
New York partner Robert Gunther is a key member of the firm’s life sciences patent litigation bench, and was honored in 2020 as the General Patent Litigator of the Year in New York for his significant activity in the area. Among his notable representations was a consolidated case for Roche and Becton Dickinson against Enzo Life Sciences, which resulted in a noteworthy Federal Circuit ruling involving enablement issues. The matter was named one of 2020’s Patent Impact Cases of the Year. IP litigation group co-chair Lisa Pirozzolo is an experienced first-chair trial lawyer who is representing several notable life sciences clients, including CSL Behring in a dispute against Biogen related to hemophilia treatment. William Lee is one of the most celebrated patent litigators in the country, offering more than four decades of experience in law. DC-based partner Amy Wigmore is currently active for Bristol-Myers Squibb and Pfizer in a Hatch-Waxman litigation opposite several generic manufacturers that at one point totaled 25 challengers.
The firm's corporate capabilities are supported by several experienced attorneys, including Steven Barrett, who co-chairs the technology transactions and licensing practice group. He recently represented Ribometrix in a collaboration with Vertex Pharmaceuticals, and Medtronic in funding agreements with Blackstone Life Sciences. Transactional department chair Lia Der Marderosian represented Pandion Theraupetics, a biotechnology company focused on autoimmune diseases, in its $80 million Series B financing. Life sciences group co-chair Stuart Falber advises a variety of life sciences clients ranging from startups to established companies in the space. He specializes in corporate and venture capital transactions, as well as licensing and collaboration agreements. Among his notable matters, Fabler advised Epizyme in its $270 million collaboration agreement with Royalty Pharma. Steven Singer has over 30 years of experience assisting both public and private life sciences companies in various transactions. A new addition to this year’s list is Cynthia Mazareas, who represents both a number of high-profile private and public life sciences companies with a variety of issued related to corporate governance and transactions.
In the enforcement area, the firm is noteworthy for its practice focused on government investigations and white-collar matters. Securities litigation practice co-chair Michael Bongiorno recently took part in an appellate matter for Ocular Therapeutix and its former officers, resulting in a First Circuit ruling that the clients did not mislead investors regarding manufacturing and regulatory aspects of drug candidate Dextenza. Howard Shapiro is chair of the firm's litigation and controversy department, with more than three decades of experience handling disputes, particularly in the area of white-collar defense.